PMS [post marketing surveillance] assessing the safety and efficacy of telmisartan in patients with mild to moderate essential hypertension.

Trial Profile

PMS [post marketing surveillance] assessing the safety and efficacy of telmisartan in patients with mild to moderate essential hypertension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 May 2012

At a glance

  • Drugs Hydrochlorothiazide; Telmisartan
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 18 May 2012 Actual patient number chnaged from (34329) to (33247) as reported by ClinicalTrials.gov.
    • 05 Mar 2010 Actual patient number (34329) added as reported by ClinicalTrials.gov.
    • 05 Mar 2010 Status change from recruiting to completed as reported by CliniclaTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top